4.7 Article

SPECT Imaging of Joint Inflammation with Nanobodies Targeting the Macrophage Mannose Receptor in a Mouse Model for Rheumatoid Arthritis

期刊

JOURNAL OF NUCLEAR MEDICINE
卷 54, 期 5, 页码 807-814

出版社

SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.112.111781

关键词

macrophage mannose receptor (MMR); collagen-induced arthritis (CIA); single photon emission computed tomography (SPECT); Nanobody

资金

  1. government agency for Innovation by Science and Technology (IWT, Belgium)
  2. Concerted Research Actions of the Regional Government of Flanders (GOA)

向作者/读者索取更多资源

Rheumatoid arthritis (RA) is a chronic autoimmune disease occurring in approximately 1% of the worldwide population. The disease primarily affects the joints, where inflammatory cells, such as macrophages, invade the synovium and cause cartilage and bone destruction. Currently, it is difficult to efficiently diagnose and monitor early-stage RA. In this study, we investigated whether SPECT/micro-CT imaging with Tc-99m-labeled Nanobodies directed against the macrophage mannose receptor (MMR) is a useful tool for monitoring and quantifying joint inflammation in collagen-induced arthritis (CIA), a mouse model for RA. The expression of MMR was analyzed on macrophages and osteoclasts generated in vitro and in cells obtained from various organs from mice with CIA. Methods: CIA was induced in DBA/1 mice by injection of collagen type II in complete Freund adjuvant, and cell suspensions from the inflamed joints and other organs were obtained. Macrophages and osteoclasts were generated in vitro from bone marrow cells. Expression of MMR was quantified by quantitative polymerase chain reaction and flow cytometry with specific Nanobodies and conventional antibodies. SPECT/micro-CT imaging was performed with Tc-99m-labeled MMR and control Nanobodies. Results: MMR was highly expressed on macrophages and to a lesser extent on osteoclasts generated in vitro. In mice with CIA, MMR expression was detected on cells from the bone marrow, lymph nodes, and spleen. In synovial fluid of arthritic joints, MMR was expressed on CD11b(+)F4/80(+) macrophages. On in vivo SPECT/micro-CT imaging with consecutive injections of MMR and control Nanobodies, a strong MMR signal was seen in the knees, ankles, and toes of arthritic mice. Quantification of the SPECT imaging confirmed the specificity of the MMR signal in inflamed joints as compared with the control Nanobody. Dissection of the paws revealed an additional significant MMR signal in nonarthritic paws of affected mice (i.e., mice displaying symptoms of arthritis in other paws). Conclusion: Our data show that MMR is expressed on macrophages in vitro and in vivo in synovial fluid of inflamed paws, whereas expression is relatively low in other tissues. The use of Nanobodies against MMR in SPECT/micro-CT imaging generates the possibility to track inflammatory cells in vivo in arthritic joints.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Correction Biochemistry & Molecular Biology

Multinucleation resets human macrophages for specialized functions at the expense of their identity (vol 24, e56310, 2023)

Kourosh Ahmadzadeh, Marie Pereira, Margot Vanoppen, Eline Bernaerts, Jeong-Hun Ko, Tania Mitera, Christy Maksoudian, Bella B. Manshian, Stefaan Soenen, Carlos D. Rose, Patrick Matthys, Carine Wouters, Jacques Behmoaras

EMBO REPORTS (2023)

Article Allergy

Homozygous DBF4 mutation as a cause of severe congenital neutropenia

Mathijs Willemsen, John S. Barber, Erika Van Nieuwenhove, Frederik Staels, Margaux Gerbaux, Julika Neumann, Teresa Prezzemolo, Emanuela Pasciuto, Vasiliki Lagou, Nancy Boeckx, Jessica Filtjens, Amber De Visscher, Patrick Matthys, Rik Schrijvers, Thomas Tousseyn, Mark O'Driscoll, Giorgia Bucciol, Susan Schlenner, Isabelle Meyts, Stephanie Humblet-Baron, Adrian Liston

Summary: This study reported a patient with severe congenital neutropenia and syndromic features, and a homozygous missense mutation in the DBF4 gene was identified using whole exome sequencing. This mutation caused defects in granulocyte differentiation and DNA replication, resulting in impaired immune system function.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Targeted a-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment

Thomas Ertveldt, Ahmet Krasniqi, Hannelore Ceuppens, Janik Puttemans, Yana Dekempeneer, Kevin De Jonghe, Wout de Mey, Quentin Lecocq, Yannick De Vlaeminck, Robin Maximilian Awad, Cleo Goyvaerts, Kim De Veirman, Alfred Morgenstern, Frank Bruchertseifer, Marleen Keyaerts, Nick Devoogdt, Matthias D'Huyvetter, Karine Breckpot

Summary: Targeted radionuclide therapy (TRT) using targeting moieties labeled with α-particle-emitting radionuclides (a-TRT) is an intensely investigated treatment approach. However, there is a lack of profound assessment of the immunomodulatory effect of a-TRT in literature.

JOURNAL OF NUCLEAR MEDICINE (2023)

Letter Medicine, General & Internal

TET2-Driver and NLRC4-Passenger Variants in Adult-Onset Autoinflammation

Ellen De Langhe, Sien Van Loo, Bert Malengier-Devlies, Mieke Metzemaekers, Frederik Staels, Jessica Vandenhaute, Nathalie Berghen, Raf Sciot, Anniek Corveleyn, Olga Tsuiko, Mieke Gouwy, Jan Lenaerts, Patrick Verschueren, Carine H. Wouters, Paul Proost, Patrick Matthys, Eric Legius, Rik Schrijvers

Summary: The article reports a case of adult-onset inflammatory disease. It is revealed that two somatic genetic events are responsible for the disease and its onset in adulthood.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Multidisciplinary Sciences

Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody

Maxime Nachit, Christopher Montemagno, Romain Clerc, Mitra Ahmadi, Francois Briand, Sandrine Bacot, Nick Devoogdt, Cindy Serdjebi, Catherine Ghezzi, Thierry Sulpice, Alexis Broisat, Isabelle A. Leclercq, Pascale Perret

Summary: In this study, researchers found that molecular imaging of VCAM-1 could be a non-invasive alternative to biopsy for detecting liver inflammation in chronic liver disease. By using radiolabeled anti-VCAM-1 nanobody and SPECT, they were able to quantify liver uptake and correlate it with histological inflammatory scores and molecular markers. The diagnostic power of this imaging tool to detect liver inflammation was excellent, suggesting its potential for clinical use.

NATURE COMMUNICATIONS (2023)

Article Pharmacology & Pharmacy

Optimizing the Safety and Efficacy of Bio-Radiopharmaceuticals for Cancer Therapy

Cyprine Neba Funeh, Jessica Bridoux, Thomas Ertveldt, Timo W. M. De Groof, Dora Mugoli Chigoho, Parinaz Asiabi, Peter Covens, Matthias D'Huyvetter, Nick Devoogdt

Summary: The combination of specific targeting vectors with radionuclides for targeted radionuclide therapy (TRT) efficiently delivers cytotoxic radiation to cancer cells, proving its value in cancer care. TRT is increasingly seen as a relevant treatment method for micro-metastases in relapsed and disseminated disease. Antibody fragments and peptides are gaining interest as superior alternatives to antibodies for TRT. Rigorous considerations in design, analysis, evaluation, and translation are crucial for the development of novel radiopharmaceuticals to ensure safety and effectiveness.

PHARMACEUTICS (2023)

Review Immunology

A few good reasons to use nanobodies for cancer treatment

Neema Ahishakiye Jumapili, Maida Zivalj, Romina Mora Barthelmess, Geert Raes, Timo W. M. De Groof, Nick Devoogdt, Benoit Stijlemans, Cecile Vincke, Jo A. Van Ginderachter

Summary: mAbs have limitations in their distribution and penetration in tumor microenvironment, as well as their ability to reach the brain. Nanobodies, being smaller in size, possess superior abilities in tumor penetration and infiltration into brain tumors. However, the rapid clearance of nanobodies from circulation may affect their suitability for therapy, although their noncovalent binding to albumin can help increase their serum half-life.

EUROPEAN JOURNAL OF IMMUNOLOGY (2023)

Review Pharmacology & Pharmacy

Current status and future expectations of nanobodies in oncology trials

Tessa De Pauw, Lynn De Mey, Jens M. Debacker, Geert Raes, Jo A. Van Ginderachter, Timo W. M. De Groof, Nick Devoogdt

Summary: Monoclonal antibodies have played a significant role in personalized medicine for cancer, but their size and complexity may hinder certain cancer diagnosis and therapy applications. Nanobodies, with their unique structure and pharmacological features, have shown promising potential as complementary tools for cancer diagnostics and therapeutics. This overview provides insights into nanobody-based diagnostics and therapeutics that have been tested in clinical trials and highlights upcoming preclinical developments.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)

Odrade Gondry, Catarina Xavier, Laurens Raes, Johannes Heemskerk, Nick Devoogdt, Hendrik Everaert, Karine Breckpot, Quentin Lecocq, Lore Decoster, Christel Fontaine, Denis Schallier, Sandrine Aspeslagh, Ilse Vaneycken, Geert Raes, Jo A. Van Ginderachter, Tony Lahoutte, Vicky Caveliers, Marleen Keyaerts

Summary: Macrophages play a vital role in the body, and anti-inflammatory macrophages targeting CD206 are involved in various diseases. This study evaluated the safety and biodistribution of a PET tracer targeting CD206 in human subjects, and found that the tracer was safe, rapidly cleared from the blood, and enabled high contrast imaging at 90 minutes after injection. Preliminary results showed higher tumor uptake in patients with disease progression.

JOURNAL OF NUCLEAR MEDICINE (2023)

Article Chemistry, Physical

Optimized cyclotron production of At-211: The challenge of Po-210-characterization

Matthijs Bart C. Sevenois, Brian WM. Miller, Holger Jan Jensen, Matthias D'Huyvetter, Peter Covens

Summary: The yield of At-211 is currently limited by the incident He2+-beam energy of the Bi-209(alpha,2n)At-211 reaction, which needs to be approximately 28 MeV to avoid co-production of At-210 and its daughter Po-210 through Bi-209(alpha,3n)At-210. However, using higher energies could significantly increase the yield of At-211, but also raises concerns regarding the production and handling of Po-210 and its toxicity.

RADIATION PHYSICS AND CHEMISTRY (2023)

Article Immunology

Biallelic mutations in the CFHR genes underlying atypical hemolytic uremic syndrome in a patient with catastrophic adult-onset Still's disease and recurrent macrophage activation syndrome: A case report

Luna Dillemans, Youri Bekhuis, Albrecht Betrains, Karen Yu, Maarten van Hemelen, Noemie Portner, Lien De Somer, Patrick Matthys, Jeroen Breckpot, Thomas Tousseyn, Marijke Peetermans, Paul Proost, Carine Wouters, Steven Vanderschueren

Summary: We report a fatal case of a 20-year-old woman with refractory adult-onset Still's disease accompanied by fulminant macrophage activation syndrome and atypical hemolytic uremic syndrome. This case highlights the importance of prompt genetic assessment of complement-encoding alleles, in addition to HLH-related genes, in patients with severe adult-onset Still's disease with recurrent macrophage activation syndrome and features of thrombotic microangiopathy.

CLINICAL IMMUNOLOGY (2023)

Meeting Abstract Oncology

Elevated LAG-3 expression in plasma cells and lymphoid subpopulations at distinct stages of multiple myeloma disease progression

Hatice Satilmis, Niels Vandewalle, Emma Verheye, Rong Fan, Elke De Bruyne, Eline Menu, Nick Devoogdt, Karin Vanderkerken, Karine Breckpot, Kim De Veirman

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

暂无数据